Therefore, we hypothesize that NLRP3 inflammasome-mediated cascade may be one of the mechanisms by which SHYZD exerts therapeutic effects on AD, and SHYZD may potentially regulate NF-κB-related pathways. Here, NLRP3 is linked to Alzheimer disease.